manipalhospitals
LIFE'S ON

Date: August 20, 2026

To,

National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

NSE Scrip Symbol: MANIPALHOS

BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.

BSE Scrip Code: 544847

Subject: Press Release and Investor Presentation for the Earnings Conference Call with Analysts and Investors of Manipal Health Enterprises Limited (the "Company")

Dear Sir/Ma'am,

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), please find enclosed the Press Release and Investor Presentation in connection with the earnings conference call scheduled to be held tomorrow, i.e., August 21, 2026, to discuss the Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended June 30, 2026.

The above information is also hosted on the website of the Company at: https://www.manipalhospitals.com

This intimation is being submitted for your information and records. Kindly take the same on record.

Thank you.

For Manipal Health Enterprises Limited
(formerly known as Manipal Health Enterprises Private Limited)

SATHISH KOLAR RAMAMOORTHY
Digitally signed by SATHISH KOLAR RAMAMOORTHY
Date: 2026.08.20 19:40:46 +05'30'

Sathish K R

Company Secretary and Compliance Officer

Membership No.: A15203

Manipal Hospitals Delivers 38.1% Revenue Growth and 26.4% EBITDA Growth in Q1 FY27

Patient-led growth and specialty care momentum support performance across the network

Bengaluru, Karnataka, August 20, 2026: Manipal Health Enterprises Limited (Manipal Hospitals), India's largest pan-India multi-specialty hospital networks by bed capacity, today announced its financial results for the quarter ended June 30, 2026 (Q1 FY27), marking its first results announcement following its listing on August 5, 2026.

The company delivered a strong operating performance during the quarter, supported by sustained patient demand, growth in high-acuity specialties and capacity absorption. Improving occupancy and operating efficiencies further strengthened the performance of the expanded network.

Operating Performance

Revenue from operations stood at ₹ 3,091 crore in Q1 FY27, registering 38.1% year-on-year growth, while EBITDA stood at ₹ 749 crore reflecting year-on-year growth of 26.4%. Excluding one-off gain of ₹ 15 crore in Q1 FY26, EBITDA growth was 29.7% year-on-year, reflecting continued operating improvement.

Inpatient and outpatient volumes grew 38.8% and 26.0%, respectively, during the quarter, while occupancy improved by 290 basis points year-on-year to 65.0% as the network continued to absorb recently added capacity.

PAT stood at ₹ 243 crore during Q1FY27. Excluding ₹ 89 crore of post-tax interest on the NCD raised for the Sahyadri acquisition, adjusted PAT grew 30.9% year-on-year. ARPOB, excluding Sahyadri, stood at ₹ 77,200 per day, up 8.7% year-on-year, reflecting improved revenue intensity across the existing network.

Sahyadri Integration Supports Growth

Sahyadri Hospitals continued to contribute to the network's performance during the quarter, with its integration progressing across clinical and operational functions.

Sahyadri recorded 12.8%* revenue growth and 18.7%* EBITDA growth year-on-year, supported by higher ARPOB and improved operating efficiency. The integration is expected to unlock further benefits through greater clinical integration, shared capabilities and operating scale.

High-Acuity Specialties Continue to Drive Momentum

Gross inpatient revenue from CONGO-R specialties grew 45% year-on-year, with the specialty mix increasing to 65.4%, highlighting continued demand for complex care.

Oncology and Orthopedics were key growth drivers, recording inpatient revenue growth of 62% and 49%, respectively, supported by broad-based momentum across the CONGO-R portfolio.

* Q1FY26 as per erstwhile management reporting since Sahyadri was acquired on October 3, 2025

manipalhospitals
LIFE'S ON

Performance Highlights:

Particulars (₹ Cr)	Q1 FY2027	Q1 FY2026*	YoY	Q4 FY2026	QoQ
Revenue from Operations	3,091	2,238	38.1%	2,882	7.2%
EBITDA	749	593[(1)]	26.4%	702	6.6%
EBITDA Margin %	24.2%	26.5%	(230) bps	24.4%	(20) bps
PAT	243[(2)]	254	(4.2)%	187	30.5%
PAT Margin %	7.9%	11.4%	(350) bps	6.5%	140 bps
ARPOB (₹/day)	71,500[(3)]	71,000	0.7%	68,500	4.4%
Occupancy %	65.0%	62.1%	290 bps	64.9%	10 bps

(1) Excluding a one-off gain of ₹15 crore in Q1 FY26, adjusted EBITDA was ₹578 crore, with **Q1 FY27 adjusted EBITDA growth of 29.7% YoY**.
(2) Excluding ₹89 crore of post-tax interest on the Sahyadri acquisition NCD, **Q1 FY27 adjusted PAT was ₹332 crore, up 30.9% YoY**.
(3) Excluding Sahyadri, Q1 FY27 ARPOB was ₹77,200 per day, representing growth of 8.7% YoY.
* Sahyadri was acquired on October 3,2025 and hence Q1FY26 numbers do not include Sahyadri.

Commenting on the Q1 FY27 performance, Dilip Jose, Managing Director & CEO, Manipal Hospitals, said:

"Q1 FY27 marks an important milestone for Manipal Hospitals as our first quarter as a listed company. Our performance this quarter reflects the strength of our Pan-India network, sustained patient demand and continued growth in high-acuity specialties. We remained focused on absorbing added capacity while maintaining clinical quality, patient outcomes and operational discipline.

The integration of Sahyadri Hospitals remains a key priority as we unlock the benefits of a larger network and greater operating scale. Our IPO provides greater flexibility to invest in capacity, technology and clinical excellence while maintaining disciplined capital allocation.

As we enter this next phase, we remain focused on expanding access, strengthening clinical outcomes, improving efficiency and building a more integrated and sustainable healthcare platform."

About Manipal Hospitals:

Manipal Hospitals is one of India's leading integrated healthcare providers serving ~ 8 million patients annually, focussed on providing accessible, high-quality healthcare services. Manipal Hospitals integrated network today has a Pan-India footprint of 50 hospitals with over 13,400 licensed beds across 14 States & Union Territories. The network is India's largest multispecialty hospital network by bed capacity, supported by a talented pool of 11,000+ doctors and an employee strength of over 25,000.

With a commitment to provide patient-centric care, Manipal Hospitals combines clinical expertise with advanced technology, research and innovation to serve a multitude of patients across the globe. Its continued focus on clinical quality and operational excellence is reflected in its NABH accreditation, with several of its hospitals also accredited by NABL and recognised for its excellence in nursing and emergency care. For more information, please visit - https://www.manipalhospitals.com/

Manipal Health Enterprises Limited

Earnings Update: Q1 FY27

manipalhospitals

LIFE'S ON

Disclaimer

This presentation is issued by Manipal Health Enterprises Limited (the “Company”) for general information purposes only, without regards to the specific objectives, financial situation or requirements of any particular person. This presentation may not be copied, published, distributed or transmitted, in whole or in part, for any purpose, and should not be construed as legal, tax, investment or other advice.

This presentation does not constitute a prospectus, placement document, offering circular or offering memorandum and is not an offer or invitation or recommendation or solicitation or inducement to buy or sell any equity shares or other securities of the Company or its Subsidiaries. This presentation shall not form the basis of, or be relied on, in connection with, any contract or investment decision in relation to any securities.

Unless otherwise stated, the information contained herein is based on management information and estimates. The information contained herein is only current as of the date specified herein, has not been independently verified and may be subject to change without notice. Please note that past performance is not indicative of future results. Please note that the recipient will not be updated in the event the information becomes stale. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. The Company as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of the content including any information or opinions contained herein. Any opinions expressed in this presentation or the contents of this presentation are subject to change without notice. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since the date of this presentation.

This presentation also contains forward-looking statements based on the currently held beliefs, opinions and assumptions of the Company. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, our occupiers and the Indian and global economies, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments or the impact of events which cannot currently be ascertained. In addition to statements which are forward looking by reason of context, the words ‘may’, ‘will’, ‘should’, ‘expects’, ‘plans’, ‘intends’, ‘anticipates’, ‘believes’, ‘estimates’, ‘predicts’, ‘potential’ or ‘continue’ and similar expressions identify forward-looking statements.

Certain information (including any guidance and proforma information) presented herein is based on management information, assumptions and estimates and is not audited or reviewed by an auditor or based on GAAP, Ind AS or any other internationally accepted accounting principles. The reader should not consider such items as an alternative to the historical financial results or other indicators of the Company’s profit, cash flows or distribution based on any GAAP.

Disclaimer

Actual results may be materially different from the expectations expressed or implied by this information, and there can be no assurance that the expectations reflected in this information will prove to be correct.

By reading this presentation the recipient acknowledges that the recipient will be solely responsible for its own investigation, assessment and analysis of the market and the market position of the Company and that the recipient will conduct its own analysis and be solely responsible for forming its own view of the potential future performance of the business of the Company. This presentation may not be all inclusive and may not contain all of the information that the recipient considers material. The distribution of this presentation in certain jurisdictions may be restricted by law. Accordingly, any persons in possession of this presentation should inform themselves about and observe any such restrictions.

None of the Company or any of their respective affiliates, advisers or representatives accept any liability whatsoever for any loss howsoever arising from any information presented or contained in this presentation. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having being authorized by or on behalf of the Company.

Investors are advised to consult their investment advisor before making an investment decision. This information should not be used or considered as financial or investment advice, recommendation or an offer for sale or a solicitation of any offer to buy any equity shares or other securities of the Company. This presentation and any of its contents do not provide for and should not be construed as any assurance or guarantee of returns or distribution to investors or the trading price of the securities.

THIS PRESENTATION DOES NOT CONSTITUTE OR FORM ANY PART OF ANY OFFER, INVITATION OR RECOMMENDATION TO PURCHASE OR SUBSCRIBE FOR ANY SHARES OR OTHER SECURITIES IN INDIA, THE UNITED STATES OR ELSEWHERE.

Table of Contents

Senior Management Profile

Mr. Dilip Jose
MD & CEO

- More than **36 years of experience** including over 23 years of experience in healthcare sector with last **8+ years at Manipal Hospitals**
- Holds a Bachelor's degree in Physics from Gandhiji University, Kottayam and a Post-graduate Diploma in rural management from the Institute of Rural Management, Anand
- Completed the Global CEO program from IESE Business School and Wharton Business School
- Previously associated with TPG Capital, HM Patel Centre for Medical Care & Education, the National Dairy Development Board, Vadilal Industries Limited, Fortis Healthcare Limited and Quality Care India Limited

Mr. Sameer Agarwal
Group CFO

- More than **28 years of experience** in the field of Finance and Accountancy with **last 10+ years at Manipal Hospitals**
- Holds a Bachelor's degree in commerce with specialization in the subject of financial accounting and auditing from Shri Narsee Monjee College of Commerce and Economics, University of Bombay. He is also a member of the ICAI
- Previously associated with 3M India Limited, Ingersoll-Rand (India) Limited, Hindustan Coca-Cola Beverages Private Limited, Marico Industries Limited, Wipro Limited and N.M. Raiji & Co.

Mr. Karthik Rajagopal
COO

- More than **19 years of experience** in operational management with **last 8+ years at Manipal Hospitals**
- Holds a Bachelor's degree in commerce from Bharathidasan University, Tiruchirappalli
- Holds a Master's degree in management from the Asian Institute of Management, Philippines
- Previously associated with DM Healthcare LLC, Fortis Healthcare Limited, Apollo Hospitals Enterprises Limited, Manipal Healthcare Private Limited, Schoolnet India Limited, Ammirati Puris Lintas, Lintas India Limited and Bennet Coleman & Company Limited

Manipal Hospitals at a Glance

Largest Pan-India Multispecialty Hospital Network by Bed Capacity

13,140 Licensed Beds across **49 Hospitals**
11,000+ Doctors, 24,700+ Employees
(As of Jun 30, 2026)

7 DECADES OF TRACK RECORD

Rich Legacy of Founders

memg
manipal education and medical group

Professionally Managed and Backed by Marquee Investors

Temasek Holdings Pvt Ltd
(through indirect wholly owned subsidiaries)

TPG SG Magazine Pte. Ltd.

Novo Holdings Invest Asia A/S

Seventy Second Investment Company LLC

manipalhospitals
LIFE'S ON

#1 in 3 Key Regions[1]**: Karnataka, Maharashtra & Goa and East India**[2]

Only Private Hospital Chain with Leadership in **3 (of 8) Metros**[3]

Widest Pan-India footprint: Present in **14 States/UT**[4]

Balanced and Diversified Presence across **Metros and Non-Metros**

Widely Recognized Network of Choice for Patients, Doctors and Healthcare Professionals

Number One Hospital in Bengaluru
The Week - Hansa Survey
(Ranked #1 for 20 years between '05-25**)**

~1,750
Robotic-assisted Spine Surgeries[7]
(amongst highest reported volumes in India)

41 NABH[5]
Accredited / Certified Hospitals

24 NABL[6]
Accredited Hospital Labs

74.6k
Angiography and Angioplasty procedures[8]

8.3k
Neuro surgeries[8]

Source: Crisil Intelligence for industry data unless otherwise mentioned
1) Largest player by licensed beds
2) Includes West Bengal, Odisha, Jharkhand and Sikkim
3) By bed capacity
4) 13 states and 1 UT as of June 30, 2026

5) National Accreditation Board for Hospitals and Healthcare Providers (As of March 31, 2026)
6) National Accreditation Board for Testing and Calibration Laboratories (As of March 31, 2026)
7) As of March 31, 2026
8) For Fiscal 2026

Pan India Hospital Network



*O&M Hospitals, which are hospitals that the group operates and manages pursuant to operation & management agreements

Key regions

Bed mix by Region

- Karnataka (19 Hospitals | 6,404 Beds) Owned: 3,119; O&M: 3,285
- West Bengal, Odisha, Jharkhand, and Sikkim (East India) (10 Hospitals | 2,887 Beds) Owned: 2,387; O&M:500
- Maharashtra & Goa (13 Hospitals | Owned: 2,291 Beds)
- Others (7 Hospitals | 1,558 Beds)

Leading Presence Across 3 Metros

Bengaluru	12 Hospitals | 2,579 Beds
Kolkata	5 Hospitals | 1,513 Beds
Pune	9 Hospitals | 1,284 Beds

Bed Split (Owned vs O&M)

Owned : 9,355[1]

Operational : 7,164

O&M : 3,785

Balanced Presence across Metro & Non-metros

Metro	Non-Metro
29 Hospitals | **6,099** Beds	20 Hospitals | **7,041** Beds
Owned: 6,099	Owned: 3,256
O&M Beds: Nil	O&M Beds: 3,785

Source: Crisil Intelligence for industry data unless otherwise mentioned

1) Also includes three hospitals operated pursuant to a joint management and collaboration agreement, a concession agreement and a memorandum of understanding and management agreement with Human Care Medical Charitable Trust ("HCMCT"), Eastern India Health Foundation ("EIHF") and Konkan Mitra Mandal Medical Trust ("KMMMT"), respectively

manipalhospitals LIFE'S ON

Q1FY27 Performance: Executive Summary

Financial Metrics

Revenue: INR 3,091 Cr
(+38.1%[1] vs Q1FY26)

EBITDA: INR 749 Cr
(+26.4%[2] vs Q1FY26,
+29.7%[3] w/o one off)

EBITDA Margin: 24.2%
(Ex-Sahyadri: 25.0%)

PAT: INR 243 Cr
(INR 332 Cr Ex-NCD int.[4],
+30.9% vs Q1FY26)

Operational Metrics

IP Volumes: 155k
(+38.8%[5] vs Q1FY26)

Occupancy: 65.0%
(+290 bps vs Q1FY26)

ALOS: 2.7 Days

ARPOB[6]: INR 71,500 / day
(INR 77,200/day, +8.7% Ex-Sahyadri)

CONGO-R Mix: 65.4%
(+70 bps vs Q1FY26)

1. Q1FY27 includes Sahyadri revenue of INR 332 Cr.
2. Q1FY27 includes Sahyadri EBITDA of INR 58 Cr.
3. Q1FY26 includes one-off gain of INR 15 Cr.
4. Sahyadri NCD interest impact (net off tax) is INR 89 Cr.
5. Q1FY27 includes Sahyadri IP volume of 26k
6. Rounded off to the nearest 100.

Note: Sahyadri was acquired on October 3,2025 and hence Q1FY26 numbers do not include Sahyadri.

Performance Highlights

India's 1st Installation of Elekta Evo LINAC, an Online Adaptive radiotherapy for next-gen cancer treatment @ our recently launched North Bengaluru facility

manipalhospitals
LIFE'S ON

Financial Highlights

Revenue (INR Cr.)



EBITDA (INR Cr.) and EBITDA Margin



PAT (INR Cr.) and PAT Margin



Net Debt (INR Cr.) and Net Debt[3] / EBITDA



1. Q1FY26 includes one-off gain of INR 15 Cr. excluding which EBITDA was INR 578 Cr.
2. Sahyadri NCD interest impact net off tax is INR 89 Cr.
3. Net Debt excludes lease liabilities. Net Debt / EBITDA on annualized basis.
4. Excludes Sahyadri NCD and interest thereon.

Note: Sahyadri was acquired on October 3,2025 and hence Q1FY26 numbers do not include Sahyadri.

Operational Highlights

of Operational Beds



Occupied beds & Occupancy %



IP Volumes (in 000s)



ARPOB (INR k/day)



ALOS (Days)



OP Volumes (in 000s)



Note: Sahyadri was acquired on October 3,2025 and hence Q1FY26 numbers do not include Sahyadri.

CONGO-R Specialties





Centre of Excellence	Cardiac	Onco	Neuro	Gastro	Ortho	Renal
Growth (y-o-y)	40%	62%	39%	35%	49%	41%

Note: Congo-R Specialties Mix based on Gross Inpatient Revenue

Advanced Clinical Equipment Delivering Excellence at Scale

Advanced Medical Infrastructure that Enables Tertiary and Quaternary Care across Our Network[1]…

19	LINACs[2]
2	Tomotherapy Units
25	Orthopedic & Spine Surgical Robots
59	Cath Labs
44	MRI[3]
19	Soft Tissue Robots
6	Gamma Cameras

Radixact Tomotherapy

LINAC

Elekta Evo Linac

J&J Ortho Robot

Da Vinci Xi Soft Tissue Robot

Intravascular Ultrasound (IVUS)

Q1 FY27 Additions

High end LINAC and PET CT @ MH Nashik



AI-assisted Neuro biplane Cath Lab system @ MH Mukundpur

Orthopedic Robo @ MH Patiala, MH Vijayawada and MH Pune Baner

AI enabled Cath Lab(Allia, GE USA) at Old Airport Road

1) Across the network, including O&M hospitals
2) Linear Accelerators
3) Magnetic Resonance Imaging

Clinical Highlights

1. MH Whitefield performs **world's first Robotic Pancreatic Surgery on a one-month-old infant** for a case of Focal Congenital Hyperinsulinism

2. MH Vijayawada successfully performed **Andhra Pradesh's first emergency living donor liver transplant** for acute liver failure due to yellow phosphorus poisoning on a 20-year-old patient

3. MH Kanakapura and MH Yelahanka **commenced the Renal transplant program in the 1st year of the hospitals operations** and did their **first robotic Renal transplants**

4. MH Gurugram achieved a significant clinical milestone by completing 40 robotic cardiac cases in 90 days via the da Vinci Surgical System

5. MH Mukundpur successfully performed an **Orbital Atherectomy-assisted PCI with LAD stenting in a high-risk 78-year-old** patient with reduced cardiac function (LVEF 39%) highlighting expertise in managing complex cardiovascular cases

6. MH Goa launched the **region's first Pulmonary Embolism Response Team (PERT), a first-of-its-kind multidisciplinary initiative** designed to enable rapid diagnosis and immediate, life-saving treatment of pulmonary embolism

7. MH Broadway successfully completed laparoscopic assisted **Whipple procedure,** a highly complex, advanced minimally invasive surgery, marking an important milestone for the hospital's surgical gastroenterology and hepatobiliary team

MH Old Airport Road earned the prestigious American Heart Association (AHA) Comprehensive Chest Pain Centre certification, rigorous, world-class benchmarks for emergency cardiac care

WSO ANGELS AWARD WINNERS Q2 2026 INDIA	
ACCORD SUPER SPECIALITY HOSPITAL, FARIDABAD	DIAMOND
ARTEMIS HOSPITAL GURUGRAM	DIAMOND
BELIEVERS CHURCH MEDICAL COLLEGE HOSPITAL, THIRUVALLA, KERALA	DIAMOND
FIRST NEURO BRAIN AND SPINE SUPER SPECIALITY HOSPITAL	DIAMOND
KOVAI MEDICAL CENTER AND HOSPITAL	DIAMOND
LALITHA SUPER SPECIALITY HOSPITALS - NEUROLOGY	DIAMOND
MEDANTA HOSPITAL, LUCKNOW	DIAMOND
MEDANTA NOIDA	DIAMOND
MEITRA HOSPITAL CALICUT KERALA	DIAMOND
SAHYADRI SUPERSPECIALITY HOSPITAL, NAGAR ROAD	DIAMOND
WINTOUCH MULTI SPECIALITY HOSPITAL	DIAMOND
RAJAGIRI HOSPITAL, ALUVA	DIAMOND

MH Sahyadri Nagar Road received WSO (World Stroke Organization) Angels Diamond Award in Q2-2026 for exceptional work in stroke management (15 Qtrs in a row)

Other Updates

manipalhospitals
LIFE'S ON

Region Wise Metrics

Karnataka Region



Particulars	Q1FY26	Q1FY27
Revenue	1,115	1,373
Operational Beds	2,028	2,294
Occupancy %	60.9%	61.1%
IP Volumes (‘000s)	43	51

Maharashtra + Goa Region

Particulars	Q1FY26	Q1FY27
Revenue	127	503
Operational Beds	352	1,680
Occupancy %	54.8%	62.5%
IP Volume (‘000s)	7	35

East India Region



Particulars	Q1FY26	Q1FY27
Revenue	530	620
Operational Beds	1,855	1,858
Occupancy %	63.8%	66.9%
IP Volume (‘000s)	35	36

Rest of India Region



Particulars	Q1FY26	Q1FY27
Revenue	407	535
Operational Beds	1,196	1,332
Occupancy %	63.8%	72.3%
IP Volume (‘000s)	27	33

Region-wise metrics are only for hospital business and excludes HealthMap revenue of INR 59 Cr. in Q1FY26 and INR 59 Cr. Q1FY27.

Structured Plan for Sahyadri Integration

	Integration Vectors	Update
Quantitative	Procurement Synergies	• Centralized pricing rates rolled out
	Efficiencies and Case Mix	• OP to IP conversion efficiencies and service excellence
	Re-branding	• Introduced co-branding for Sahyadri hospitals • Phased introduction of Digital revenue initiatives
Qualitative	People	• Regional leadership team in place along with grade alignment • Clinical talent addition (82) & Inter-operability of clinicians (58)
	Infrastructure	• LINAC launched at Nashik facility; Brownfield bed addition:103 • Construction commenced for Wakad greenfield project
	Governance & Practices	• Commenced Big-Four Quarterly Audit & Internal Audit processes • Cybersecurity, VAPT & DPDP assessment completed • Completed Life Fire & Safety Audit

Revenue: INR 332 Cr
(+12.8% vs Q1FY26[1], +11.7% vs Q4FY26)

EBITDA: INR 58 Cr
(+18.7% vs Q1FY26[1], +61.2% vs Q4FY26)

ARPOB: INR 44,800 / day
(+14.7% vs Q1FY26[1], +8.6% vs Q4FY26)

Occupancy: 62.6%
(-100 bps vs Q1FY26[1], +110 bps vs Q4FY26)

ALOS: 2.8 days
(-7.6% vs Q1FY26[1], -4.1% vs Q4FY26)

1) Q1FY26 as per erstwhile management reporting since Sahyadri was acquired on October 3, 2025.

Annexures

manipalhospitals
LIFE'S ON

Income Statement

Particulars (INR Cr.)	Q1FY27	Q4FY26	Q1FY26	FY26
Revenue from operations	3,090.6	2,882.4	2,237.6	10,335.8
Less: Cost of materials consumed	626.1	587.7	456.6	2,116.2
Less: Employee benefits expense (excluding ESOP expenses)	449.6	379.9	328.1	1,457.1
Less: Other expenses	1,265.9	1,212.1	860.4	4,118.3
EBITDA	749.0	702.7	592.5	2,644.2
Less: ESOP expenses	12.4	11.5	6.1	33.0
Add: Other Income	74.6	35.5	48.4	184.8
Less: Finance costs	293.3	289.2	131.6	864.3
Less: Depreciation and amortization expense	187.2	184.7	140.6	679.5
Profit before exceptional items and tax	330.7	252.8	362.6	1,252.2
Add: Exceptional items	(15.5)	(8.9)	(18.4)	(74.1)
Profit before tax	315.2	243.9	344.2	1,178.1
Less: Tax expense	71.8	57.4	90.2	261.5
Profit after tax	243.4	186.5	254.0	916.6

Notes:

1. Rent reversal under Ind-AS 116 is INR 49 Cr. for Q1FY27, INR 43 Cr. for Q4FY26, INR 33 Cr. for Q1FY26 and INR 156 Cr. for FY26.
2. Interest cost on NCD taken for Sahyadri acquisition (net off tax) is INR 89 Cr. Excluding this would have resulted in a PAT of INR 332 Cr.

Thank You